Research ExplorerScientific StaffKatja Weisel Publications

Prof.Dr.med. ID: 6488383

Katja Weisel

graph of relations
Affiliations
251 - 260 out of 260Page size: 50
Sort by: Title

Publications

  1. The BCL2 E17 and SP66 antibodies discriminate 2 immunophenotypically and genetically distinct subgroups of conventionally BCL2-"negative" grade 1/2 follicular lymphomas

    Adam, P., Baumann, R., Schmidt, J., Bettio, S., Weisel, K., Bonzheim, I., Fend, F. & Quintanilla-Martínez, L., 09.2013, In: HUM PATHOL. 44, 9, p. 1817-26 10 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  2. The biological and clinical impact of deletions before and after large chromosomal gains in multiple myeloma

    Cirrincione, A. M., Poos, A. M., Ziccheddu, B., Kaddoura, M., Baertsch, M-A., Maclachlan, K. H., Chojnacka, M., Diamond, B. T., John, L., Reichert, P., Huhn, S., Blaney, P., Gagler, D. C., Rippe, K., Zhang, Y., Dogan, A., Lesokhin, A. M., Davies, F. E., Goldschmidt, H., Fenk, R., Weisel, K. C., Mai, E. K., Korde, N., Morgan, G. J., Usmani, S. Z., Landgren, O., Raab, M. S., Weinhold, N. & Maura, F., 15.08.2024, In: BLOOD. 144, 7, p. 771-783 13 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  3. The prognostic and predictive value of IKZF1 and IKZF3 expression in T-cells in patients with multiple myeloma

    Awwad, M. H. S., Kriegsmann, K., Plaumann, J., Benn, M., Hillengass, J., Raab, M. S., Bertsch, U., Munder, M., Weisel, K., Salwender, H. J., Hänel, M., Fenk, R., Dürig, J., Müller-Tidow, C., Goldschmidt, H. & Hundemer, M., 2018, In: ONCOIMMUNOLOGY. 7, 10, p. e1486356

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  4. Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group

    Moreau, P., Kumar, S. K., San Miguel, J., Davies, F., Zamagni, E., Bahlis, N., Ludwig, H., Mikhael, J., Terpos, E., Schjesvold, F., Martin, T., Yong, K., Durie, B. G. M., Facon, T., Jurczyszyn, A., Sidana, S., Raje, N., van de Donk, N., Lonial, S., Cavo, M., Kristinsson, S. Y., Lentzsch, S., Hajek, R., Anderson, K. C., João, C., Einsele, H., Sonneveld, P., Engelhardt, M., Fonseca, R., Vangsted, A., Weisel, K., Baz, R., Hungria, V., Berdeja, J. G., Leal da Costa, F., Maiolino, A., Waage, A., Vesole, D. H., Ocio, E. M., Quach, H., Driessen, C., Bladé, J., Leleu, X., Riva, E., Bergsagel, P. L., Hou, J., Chng, W. J., Mellqvist, U-H., Dytfeld, D., Harousseau, J-L., Goldschmidt, H., Laubach, J., Munshi, N. C., Gay, F., Beksac, M., Costa, L. J., Kaiser, M., Hari, P., Boccadoro, M., Usmani, S. Z., Zweegman, S., Holstein, S., Harrison, S., Nahi, H., Cook, G., Mateos, M-V., Rajkumar, S. V., Dimopoulos, M. A. & Richardson, P. G., 03.2021, In: LANCET ONCOL. 22, 3, p. e105-e118

    Research output: SCORING: Contribution to journal › SCORING: Review article › Research

  5. Treatment Patterns, Survival, Quality of Life, and Healthcare Resource Use Among Patients With Triple-Class Refractory Multiple Myeloma in US Clinical Practice: Findings From the Connect MM Disease Registry

    Lee, H. C., Ramasamy, K., Weisel, K., Abonour, R., Hardin, J. W., Rifkin, R. M., Ailawadhi, S., Terebelo, H. R., Durie, B. G. M., Tang, D., Joshi, P., Liu, L., Jou, Y-M., Che, M., Hernandez, G., Narang, M., Toomey, K., Gasparetto, C., Wagner, L. I. & Jagannath, S., 02.2023, In: CL LYMPH MYELOM LEUK. 23, 2, p. 112-122 11 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  6. Treatment with Thalidomide and Cyclophosphamide (TCID) is Superior to Vincristine (VID) and to Vinorelbine (VRID) Regimens in Patients with Refractory or Recurrent Multiple Myeloma

    Auel, B., Goldschmidt, H., Geer, T., Moehler, T. M., Platzbecker, U., Naumann, R., Blau, I., Hänel, M., Knauf, W., Nückel, H., Salwender, H-J., Scheid, C., Weisel, K., Gorschlüter, M., Glasmacher, A., Schmidt-Wolf, I. G. H. & German Refractory Myeloma Study Group, 06.2012, In: INDIAN J HEMATOL BLO. 28, 2, p. 67-76 10 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  7. VTd-PACE and VTd-PACE-like regimens are effective salvage therapies in difficult-to-treat relapsed/refractory multiple myeloma: a single-center experience

    Ghandili, S., Alihodzic, D., Wiessner, C., Bokemeyer, C., Weisel, K. & Leypoldt, L. B., 01.2023, In: ANN HEMATOL. 102, 1, p. 117-124 8 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  8. What do hematologists and oncologists consider necessary for their career?: Results of an online survey in Germany, Austria and Switzerland

    Giesler, M., Busson-Spielberger, M., Miemietz, B., de Wit, M., Weisel, K. & Lüftner, D., 07.2023, In: J CANCER RES CLIN. 149, 8, p. 5331-5344 14 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  9. Whole-body diffusion-weighted MRI with apparent diffusion coefficient mapping for early response monitoring in multiple myeloma: preliminary results

    Horger, M., Weisel, K., Horger, W., Mroue, A., Fenchel, M. & Lichy, M., 06.2011, In: AM J ROENTGENOL. 196, 6, p. W790-5

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  10. Wnt1 overexpression leads to enforced cardiomyogenesis and inhibition of hematopoiesis in murine embryonic stem cells

    Weisel, K. C., Kopp, H-G., Moore, M. A. S., Studer, L. & Barberi, T., 05.2010, In: STEM CELLS DEV. 19, 5, p. 745-51 7 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Previous 12 3 4 5 6 Next